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Abstract
Background: Impedance is an integral property of neuromodulation devices that determines the current delivered to brain tissue. Long-term variability in
therapeutic impedance following deep brain stimulation (DBS) has not been extensively investigated across different brain targets. The aim was to evaluate DBS
impedance drift and variability over an extended postoperative period across common DBS targets.
Methods: Retrospective data from 1,764 electrode leads were included and drawn from 866 DBS patients enrolled in the University of Florida Institutional
Review Board-approved INFORM database and analyzed up to 84 months post implantation. An exploratory analysis was conducted to identify trends in
impedances using a Mann–Kendall test of trend.
Results: There were 866 patients and 1,764 leads available for analysis. The majority of subjects had Parkinson’s disease (60.7%). The mean age at implantation
was 58.7 years old and the mean follow-up time was 36.8 months. There were significant fluctuations in the mean impedance of all electrodes analyzed that largely
stabilized by 6 months except for the subthalamic nucleus (STN) target, in which fluctuations persisted throughout the duration of follow-up with a continued
downward trend (p , 0.001).
Discussion: The drift in impedance observed primarily within the first 6 months is in keeping with prior studies and is likely due to surgical micro-lesioning effects
and brain parenchyma remodeling at the electrode–tissue interface, typically at values approximating 1,000 V. The differences in impedance trends over time in the
various DBS targets may be due to underlying differences in structure and tissue composition.
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Introduction
Deep brain stimulation (DBS) is an invasive neuromodulatory
therapy that has been utilized for the treatment of selected patients
with movement and psychiatric disorders.1 DBS is currently Food and
Drug Administration approved for use in Parkinson’s disease (PD),
dystonia, essential tremor (ET), and obsessive–compulsive disorder.2–5
It is under investigation for several other conditions including Tourette
syndrome, depression and obesity.6–8 Although the therapeutic bene-
fit from DBS is well established, the biological response and the
mechanisms of action of DBS, as well as its long-term stability, remain
unknown.9,10 Recent studies continue to focus on the electrical stability
of DBS devices and the evaluation of device–tissue interactions across
multiple brain targets and disorders.11–13
The simplest measure of device–tissue interaction is impedance,
which is the resistance to electrical charge flow.14 With respect to DBS,
impedance depends on electrode composition and the tissue–electrode
interface. Large deviations in impedance can reflect issues in device
functionality such as short circuits, migration of cerebrospinal fluid,
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and open circuits. Values less than 50 V likely represent a short circuit,
and values greater than 2,000 V usually represent a broken lead.15
Studies measuring impedance in epileptic foci reported an initial
period of instability, followed by a general convergence of impedances
across patients.11 However, within the context of DBS, impedance
studies are usually limited to within-subject analyses.16 Investigating
impedance drift over time across subjects requires large sample sizes
due to the wide range of factors including the choice of anatomical
target, clinical diagnosis, and stimulation settings.
In this study, we present the long-term (up to 7 years) review of
impedance measurements that were drawn from over 800 patients
implanted with DBS in the subthalamic nucleus (STN), the globus
pallidus internus (GPi), or the nucleus ventralis intermedius (VIM).
We also examined impedance measurements from a few less-common
brain targets and report available information from these targets.
We discuss potential sources for deviations in impedance measure-
ments, particularly between DBS targets.
Methods
Study subjects
Data were retrospectively collected following Institutional Review
Board approval to access the University of Florida (UF) INFORM
(Center for Movement Disorders & Neurorestoration) database.
Patient data from 866 patients with 1,764 DBS leads were extracted
from the database. The UF INFORM is a longitudinal clinical
research database, which provides information on patient demo-
graphics, and clinical, surgical, and functional characteristics of patients.
Currently, the database has approximately 10,000 patients, including
all DBS patients implanted at the University of Florida. Pertinent
recorded data reviewed included indication for surgery, stimulator
model, implantation site, implantation date, laterality of implant,
therapeutic impedance measurement (measured at each follow-up
visit), stimulation settings (measured at each follow-up visit), age, and
gender. All patients in this study had either a Medtronic Soletra,
Medtronic Inc., Minneapolis, MN, USA or Kinetra implantable pulse
generator (IPG) and used a Medtronic 3387 lead. All DBS systems in
this study utilized constant voltage stimulation settings.
Following implantation, patients attended clinical follow-up visits for
DBS programming. A trained clinical programmer assessed the thera-
peutic effectiveness of stimulation settings at each follow-up visit until a
clinically defined best therapeutic setting was achieved (frequency,
voltage, pulse width, active DBS contact(s), and lead location). The
therapeutic impedance was measured with stimulation parameters
thought to provide the best clinical benefit with no side effects. Data
were derived from each programming visit, typically monthly for the
first 6 months and then once or twice a year thereafter, as determined by
individualized patient care. Impedance values in this study refer to the
therapeutic impedance measurement at the clinically defined best setting
from the active DBS contact. The therapeutic impedance was measured
at the end of each clinic visit after all programming changes were made.
Database processing
The database was parsed for patient demographics, implantation
indication, site, and laterality. Implantation sites with fewer than
10 total leads documented in the database were excluded from this
query. Once this initial query was completed, a second iteration was
performed to incorporate stimulation settings including the voltage,
frequency, pulse width and the therapeutic impedance. Group stimu-
lation settings were determined by calculating the mean and standard
deviation of the patients in the dataset. Time was defined as the
number of months since DBS implantation. As clinical parameters
dictated patient follow-up, visits were more variable and irregular with
increasing time from the date of implantation. To accommodate for
this variability, time ranges rather than dates were used to encompass
as many patient visits as possible and this method allowed for various
issues including scheduling conflicts, transportation issues, and other
barriers to scheduled clinic visits.
We examined programming settings across subjects for patient
demographics, anatomical targets, implantation laterality, and diag-
noses. Values were drawn from the first visit occurring between 18 and
30 months post implantation (i.e., 24 ¡ 6 months).
The therapeutic impedance measurements were also compared
against time. Time points for each impedance measurement were
calculated by determining the number of months between the date of
the clinic visit and the date of implantation. The impedances of the
three most frequently selected target sites (GPi, STN, and VIM) were
plotted against time up to a maximum of 84 months’ follow-up.
For each month from 0 to 84, the mean impedance and standard error
of the mean were calculated from all recorded visits for each respec-
tive target site. A composite calculation was also performed to deter-
mine the mean impedance and standard error of the mean from all
electrodes for each month. Impedance measurements of ‘‘NULL’’ or
zero were excluded from this analysis as they were deemed to be
erroneous measurements (n 5 1178). Measurements at 2,000 V and
4,000 V were excluded as they likely represented a device or recording
malfunction causing a reading greater than the maximum device
threshold (n 5 376). These values were chosen based on the technical
specifications described in the Medtronic application manual for the
Soletra and Kinetra IPGs that listed the maximum device impedance
as 2,000 and 4,000 V respectively. Additionally, impedance measure-
ments over 9,000 V were excluded (n 5 6) as they were considered
to be either erroneous or likely associated with mechanical failure.15
Impedance measurements from clinic visits that preceded the surgery
date were also excluded as they were thought to be erroneously
recorded or represented patients who underwent DBS surgery at an
outside facility and were referred to our clinic for evaluation of DBS
failure with subsequent lead revision (n 5 164). A total of 8,322
time points remained for analysis. After the mean impedances were
determined, a Mann–Kendall test of trend was performed to evaluate
for evidence of upward or downward trend in impedance over time.
A Wilcoxon signed rank test was also performed on the mean impe-
dances of all electrodes from months 0 to 12. Both the Mann–Kendall
test and the Wilcoxon signed rank test were chosen as we did not
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assume the impedance measures to be normally distributed. An alpha
level was set at 0.05 (i.e., a confidence level of 95%). All the statistical
analyses and calculations were performed using MathWorks MATLAB
R2015b and IBM SPSS Statistics 24.
Results
Patient records from 866 patients with 1,764 leads were collected for
analysis. A total of 8,322 lead measurements were utilized in the study
after the exclusion criteria were applied. Forty-five percent of patients
received unilateral DBS; all others (n 5 389) received bilateral DBS.
A summary of implantation sites and indications for DBS is shown in
Table 1. The majority of the subjects included in this study had PD
(60.7%). The mean age at implantation was 58.7 years. Of patients,
35.6% were female and 54.5% of leads were placed in the left hemi-
sphere. The mean follow-up time was 36.8 months and the maximum
follow-up time was 143 months. A visualization of the relationship
between the patient’s primary diagnosis and implantation site is sum-
marized in Table 2. A comprehensive breakdown of indication, lead
location, gender, average stimulation settings, and average impedance
is available in Table 3.
Impedance measurements were analyzed as a function of time post
implantation. The results are shown in Figure 1. There were signifi-
cant fluctuations in the mean impedance of all electrodes, but these
changes stabilized by the sixth month for all lead locations except for
the STN, where fluctuations persisted throughout the duration of
follow-up. For all recorded electrodes, Wilcoxon signed rank tests were
performed individually between the impedance at 12 months and
month 0 to month 11. We found that the mean at months 0–5 were
significantly different from the mean at 12 months (p , 0.001). There
was no significant difference in the mean impedances from month 6–11
versus month 12 by the Wilcoxon signed rank test. This finding sug-
gested that impedance tended to fluctuate most within the first
6 months.
To investigate impedance fluctuations further, we assessed for trends
using a Mann–Kendall test of trend across electrodes and separated by
DBS brain targets (Figure 1B–D). Although the Mann–Kendall test is
primarily used for monotonic trends, it has been extensively used in the
environmental sciences literature to evaluate cyclic trends such as in
annual rain fall and water quality surveillance.17–19 In this scenario,
the Mann–Kendall test evaluates the global trend but is unable to
interpret any single cycle trends. With respect to the impedance data
shown in Figure 1, we can analyze the degree of trend over time but
are unable to comment on month-to-month changes. In the composite
dataset of all electrodes, there was evidence of significant downward
trending from months 0 to 23 (p , 0.043) but downward trending
from months 24 to 84 was not significant (p 5 0.058). The Tau b
coefficients (the degree of trending measured by the Mann–Kendall
test) were –0.612 and –0.166 respectively. In the STN target, there was
evidence of significant downward trending including all 84 months
of follow-up (p 5 1.00 6 10–13). The Tau b coefficient was –0.552.
In the GPi target, there was no statistical evidence of upward or
downward trending for all 84 months (p 5 0.195). The Kendall Tau b
correlation coefficient was –0.0958. In the VIM target, there was
evidence of downward trending from months 0 to 27 (p , 0.036);
however, from months 28 to 84 there was no evidence of trending
(p 5 0.079). The Tau b coefficients were –0.305 and –0.159 respectively.
Discussion
Our study found that impedance drift was most prominent within
the first 6 months following DBS implantation. Following this initial





































Implantation site, mean (SD)
Subthalamic nucleus
Globus pallidus internus
Ventralis intermedius of thalamus
Ventralis oralis posterior/anterior of thalamus
Anterior limb of internal capsule














Total number of leads 1,764
Abbreviation: SD, Standard Deviation.
The number of implanted leads within various targets and
for different disorders and the summary statistics of the
patient population from which these results were derived are
shown. In the supplementary methods is a more complete
summary of the dataset with additional information.
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Table 2. Patient Diagnoses and Targets
Diagnosis STN GPi VIM Voa/Vop ALIC CM
Primary diagnosis, N
Parkinson’s disease 403 223 23 3 0 0
Essential tremor 5 2 168 4 0 0
Primary dystonia 19 108 7 0 0 0
Tremor (not otherwise specified) 4 0 31 27 0 0
Secondary dystonia 10 19 2 1 0 0
Obsessive compulsive disorder 0 0 0 0 12 0
Tourette syndrome 0 2 2 0 0 4
Other 8 18 4 1 0 0
Not specified 239 72 95 3 1 6
Abbreviations: ALIC, Anterior Limb of Internal Capsule; CM, Centromedian Nucleus of the Thalamus; GPi, Globus Pallidus Internus; STN,
Subthalamic Nucleus; VIM, Ventralis Intermedius of Thalamus; Voa/Vop, Ventralis Oralis Posterior/Anterior of Thalamus.
The table shows a summary of the various DBS implantation target sites with respect to the primary patient diagnosis.
Table 3. Summary Statistics




















































Implantation site, mean (SD)
Globus pallidus internus
Subthalamic nucleus
Ventralis intermedius of thalamus
Ventralis oralis posterior/anterior







































Abbreviation: SD, Standard Deviation.
The table shows a comprehensive breakdown of average stimulation settings and impedance seen at approximately 24 months post implantation
grouped by gender, age, indication and lead location.
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period, changes in impedance were more subtle but overall trended
downward with time in all targets except in the GPi. The stability
of the GPi and downward trend of other targets were consistent
with observations from previously performed smaller studies.12,14,20,21
These changes in impedance have been attributed to cerebral edema
and inflammation secondary to surgical micro-lesioning effects and
due to foreign body responses as the brain parenchyma remodels to
accommodate the electrode–tissue interface; however, this explanation
remains unconfirmed in the human brain.12,13,15,22 In this study, the
therapeutic impedance from all implantation sites equalized toward
Figure 2. Constant Voltage vs. Constant Current. The characteristics of a constant-voltage device can be seen in A–C and constant current device in D–F.
The blue box highlights a key feature of constant-current devices: regardless of physiologic impedance, the amount of current stimulation delivered to the target
tissue will always be the same.
Figure 1. Average Impedance of Deep Brain Stimulation Electrode Leads Versus Time. The solid center blue line represents the average impedance of
all electrode measurements of the specified target site: (A) for all targets, (B) for subthalamic nucleus, (C) for globus pallidus internus, and (D) for ventralis intermedius
of thalamus at 1-month intervals from 0 to 84 months. The shaded region above and below the line represents two standard errors of the mean. Asterisk with bar
indicates p , 0.001 difference from average impedance at month 12.
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the range of approximately 1000 V, presumably as the electrode–tissue
interface stabilized. Downward trends in impedance weakened with
continued follow-up over time, supporting the idea of stabilization
of the electrode–tissue interface. One limitation of this retrospective
analysis is the significant decrease in clinic visits after 60 months of
follow-up. As such, the variability of impedance in all targets after
60 months is much higher than prior to 60 months. This is likely due to
the decrease in sample size rather than changes to the electrode–tissue
interface.
While impedance in the GPI target was relatively stable throughout
the duration of follow-up, impedance in the STN continued to trend
downward throughout the entire 84 months of clinical follow-up.
One main component of impedance variability in DBS is the degree
of tissue encapsulation as a foreign body reaction to the DBS elec-
trode and the conductivity of that encapsulation.15 It is thought that
electrical stimulation can modify the tissue architecture of the
immediate vicinity, causing an increase in conductivity and decrease
in impedance. The long-term findings of this study may suggest that
the encapsulation response in the STN is not entirely identical to that
of the GPi. This may also be related to the underlying structural
differences between the two regions as well as due to the chemical
composition of the tissue and neurotransmitters that primarily con-
stitute affected neural structures.23 Researchers have proposed that
differences in the gray to white matter ratio and corresponding
distribution of peri-electrode CSF could play a role in the conductance
of the overall system.8 It is also thought that these factors may be tied
to the underlying encapsulation response, although no studies have
definitively described this relationship yet.
Impedance at the electrode–tissue interface is an important factor
that can influence the current delivered by DBS. In traditional con-
stant voltage DBS devices, it may be particularly important since
electrode impedance directly correlates to the amount of electrical
current delivered to the brain tissue (Ohm’s law: V 5 IR). In constant
current devices, the impedance plays a lesser role since the output
voltage is regulated to maintain a specified current independent of the
local impedance. The electrophysiologic differences between these two
types of devices are demonstrated with hypothetical data in Figure 2.
Though some degree of impedance drift is an expected phenomenon
that clinicians should be aware of, the overall stability of impedance
demonstrated in this large database cohort study may explain why
clinicians have not observed dramatic differences in outcomes between
constant current and constant voltage.24 To date, there have been
no large studies that have directly compared constant current DBS
devices against constant voltage devices. Smaller studies have revealed
constant current devices to be similar in safety and efficacy when
compared to constant voltage devices.25,26 Additionally, there have
been subtle differences documented in impedance among the various
brain implantation sites and this may be related to inherent tissue
properties and composition. Future studies should investigate potential
correlations between age, stimulation settings, therapeutic impedance,
disease states, and clinical outcomes and these studies should provide a
more structured follow-up.
Conclusions
The large database cohort assessed in our study provided a unique
opportunity to evaluate the impedances of empirically determined
stimulation settings for a large number of brain targets and regions.
Impedance drift occurs primarily in the first 6 months post DBS
implantation, and downward trends (when present) weaken over time.
Fluctuations in impedance are most prominent and downward trends
most persistent in the STN target, which may be due to differences in
structure and tissue composition when compared with GPI DBS.
These results suggest that constant current devices could be more
effective in maintaining impedance stability. Further investigations of
the relationship between impedance and other DBS parameters could
possibly streamline the process of initial DBS programming after
implantation and may aid in the optimization of DBS programming
settings.
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